9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in treatments for rare digestive diseases, gastrointestinal conditions, and debilitating disorders. The company's primary focus is on developing innovative therapies such as Larazotide, a peptide in Phase 3 clinical trial for celiac disease, and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 in Phase 2 clinical trial for short bowel syndrome. Additionally, the company is working on NM-102, NM-003, NM-136, and NM-004, targeting various medical conditions. These products form the core of 9 Meters Biopharma's revenue generation strategy.

Products

• Larazotide for celiac disease

• Vurolenatide for short bowel syndrome

• NM-102, NM-003, NM-136, and NM-004 for various medical conditions